Literature DB >> 11867344

Elastolysis by proteinase 3 and its inhibition by alpha(1)-proteinase inhibitor: a mechanism for the incomplete inhibition of ongoing elastolysis.

Qi-Long Ying1, Sanford R Simon.   

Abstract

An excess of proteinase 3 (Pr3) is an assumed risk factor for elastin loss in chronic obstructive pulmonary disease. This study compared the degradation of [(14)C]elastin by Pr3 and its inhibition by alpha(1)-proteinase inhibitor (alpha(1)-PI) with the analogous reactions involving two other neutrophil serine proteases, human leukocyte elastase (HLE) and cathepsin G (CatG). The elastolytic rate catalyzed by Pr3 was estimated to be half of that of CatG and one-eighth of that of HLE. Evidence was obtained that indicated that absorption of Pr3 by the substrate was much less than that of HLE or CatG, and that the majority of absorbed Pr3 was highly mobile. These properties are consistent with the observation that elastolysis by Pr3 was almost completely and stoichiometrically inhibited by alpha(1)-PI even under conditions in which the protease had been preincubated with the substrate. In contrast, alpha(1)-PI in large molar excess was unable to inhibit completely ongoing elastolysis of the same substrate by HLE or CatG. An interfacial nonisotropic reaction mechanism has been proposed to address the incomplete inhibition of ongoing elastolysis. Pr3 was identified as being the most abundant neutrophil serine protease. However, two findings reported here, namely the low rate of elastolysis by Pr3 and the high efficacy of alpha(1)-PI against ongoing elastolysis by Pr3, imply that Pr3 might not necessarily be a major contributor to neutrophil-mediated elastin loss.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11867344     DOI: 10.1165/ajrcmb.26.3.4704

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  5 in total

1.  Proteinase 3 contributes to transendothelial migration of NB1-positive neutrophils.

Authors:  Christopher J Kuckleburg; Sarah B Tilkens; Sentot Santoso; Peter J Newman
Journal:  J Immunol       Date:  2012-01-20       Impact factor: 5.422

2.  Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model.

Authors:  A Mario Marcondes; Xiang Li; Laura Tabellini; Matthias Bartenstein; Julia Kabacka; George E Sale; John A Hansen; Charles A Dinarello; H Joachim Deeg
Journal:  Blood       Date:  2011-09-06       Impact factor: 22.113

3.  α-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease.

Authors:  Nicola J Sinden; Michael J Baker; David J Smith; Jan-Ulrich Kreft; Timothy R Dafforn; Robert A Stockley
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-01-15       Impact factor: 5.464

Review 4.  The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals.

Authors:  Danielle M Dunlea; Laura T Fee; Thomas McEnery; Noel G McElvaney; Emer P Reeves
Journal:  J Inflamm Res       Date:  2018-03-26

5.  C3d Elicits Neutrophil Degranulation and Decreases Endothelial Cell Migration, with Implications for Patients with Alpha-1 Antitrypsin Deficiency.

Authors:  Laura T Fee; Debananda Gogoi; Michael E O'Brien; Emer McHugh; Michelle Casey; Ciara Gough; Mark Murphy; Ann M Hopkins; Tomás P Carroll; Noel G McElvaney; Emer P Reeves
Journal:  Biomedicines       Date:  2021-12-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.